Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
Facing partnership setbacks and pipeline pressure, Editas Medicine lays off 65% of its staff and pivots toward its …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
Clinical research in 2024 is progressing rapidly, driven by pioneering studies, technological innovation, and evolving regulatory frameworks that …
Already a subscriber? Log in